MX344915B - Anticuerpos recombinantes contra el factor de crecimiento del endotelio vascular (vegf) obtenidos mediante mutagenesis de regiones variables. - Google Patents

Anticuerpos recombinantes contra el factor de crecimiento del endotelio vascular (vegf) obtenidos mediante mutagenesis de regiones variables.

Info

Publication number
MX344915B
MX344915B MX2013007645A MX2013007645A MX344915B MX 344915 B MX344915 B MX 344915B MX 2013007645 A MX2013007645 A MX 2013007645A MX 2013007645 A MX2013007645 A MX 2013007645A MX 344915 B MX344915 B MX 344915B
Authority
MX
Mexico
Prior art keywords
vegf
mutagenesis
growth factor
antibodies
human
Prior art date
Application number
MX2013007645A
Other languages
English (en)
Other versions
MX2013007645A (es
Inventor
Cowley Jorge Victor Gavilondo
Avila Marta Ayala
Ordas Humberto Lamdan
POZO Yasmiana MUÑOZ
Meriño Amaury Pupo
Rojas Dorantes Gertrudis
PÉREZ SÁNCHEZ Lincidio
Original Assignee
Ct Ingenieria Genetica Biotecnologia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Ingenieria Genetica Biotecnologia filed Critical Ct Ingenieria Genetica Biotecnologia
Publication of MX2013007645A publication Critical patent/MX2013007645A/es
Publication of MX344915B publication Critical patent/MX344915B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1021—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against cytokines, e.g. growth factors, VEGF, TNF, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención se refiere a anticuerpos recombinantes humanos que reconocen el Factor de Crecimiento del Endotelio Vascular-A (VEGF-A) humano, bloquean su interacción con el receptor VEGFR2, e interfieren con sus efectos proliferativos in vitro y pro-angiogénicos in vivo; estos anticuerpos identifican un epítope en el VEGF-A humano diferente a cualquier otro reportado antes y se obtuvieron combinando una misma región variable de cadena ligera de inmunoglobulinas, con otras tres de cadena pesada; los anticuerpos se obtuvieron mediante mutagénesis de regiones variables de inmunoglobulinas humanas, y pueden emplearse para la inmunoterapia de entidades patológicas cuyo curso esté asociado al aumento de la vasculatura, tales como la degeneración macular asociada a la edad, el cáncer y otras.
MX2013007645A 2010-12-28 2011-12-26 Anticuerpos recombinantes contra el factor de crecimiento del endotelio vascular (vegf) obtenidos mediante mutagenesis de regiones variables. MX344915B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CU20100264A CU23895B1 (es) 2010-12-28 2010-12-28 Anticuerpos recombinantes contra el factor de crecimiento del endotelio vascular (vegf) obtenidos mediante mutagénesis de regiones variables
PCT/CU2011/000009 WO2012089176A1 (es) 2010-12-28 2011-12-26 Anticuerpos recombinantes contra el factor de crecimiento del endotelio vascular (vegf) obtenidos mediante mutagenesis de regiones variables

Publications (2)

Publication Number Publication Date
MX2013007645A MX2013007645A (es) 2013-12-02
MX344915B true MX344915B (es) 2017-01-10

Family

ID=45768110

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013007645A MX344915B (es) 2010-12-28 2011-12-26 Anticuerpos recombinantes contra el factor de crecimiento del endotelio vascular (vegf) obtenidos mediante mutagenesis de regiones variables.

Country Status (18)

Country Link
US (1) US9505830B2 (es)
EP (1) EP2662388B1 (es)
JP (1) JP6082698B2 (es)
KR (1) KR101896108B1 (es)
CN (1) CN103370336B (es)
AR (1) AR084618A1 (es)
AU (1) AU2011352474B2 (es)
BR (1) BR112013016684A2 (es)
CA (1) CA2823233C (es)
CU (1) CU23895B1 (es)
ES (1) ES2687183T3 (es)
MX (1) MX344915B (es)
MY (1) MY166550A (es)
RU (1) RU2557309C2 (es)
TW (1) TWI555757B (es)
UY (1) UY33844A (es)
WO (1) WO2012089176A1 (es)
ZA (1) ZA201305031B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
CL2014002941A1 (es) * 2014-10-30 2015-04-06 Univ Concepcion Moléculas polipeptídicas contra el factor de crecimiento del endotelio vascular (vegf)
AU2016381964B2 (en) 2015-12-30 2024-02-15 Kodiak Sciences Inc. Antibodies and conjugates thereof
CN111511400A (zh) 2017-12-29 2020-08-07 豪夫迈·罗氏有限公司 抗vegf抗体及其使用方法
JP2022514362A (ja) * 2018-12-21 2022-02-10 エフ．ホフマン－ラ ロシュ アーゲー 抗ｖｅｇｆ抗体のｖｅｇｆ－ｒ１への結合阻害を改善する方法
WO2021072265A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
CU20210101A7 (es) 2021-12-15 2023-07-12 Ct Ingenieria Genetica Biotecnologia Polipéptidos que se unen a factores de crecimiento proangiogénicos

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0672142T3 (da) 1992-12-04 2001-06-18 Medical Res Council Multivalente og multispecifikke bindingsproteiner samt fremstilling og anvendelse af disse
US5730977A (en) 1995-08-21 1998-03-24 Mitsui Toatsu Chemicals, Inc. Anti-VEGF human monoclonal antibody
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
CU23636A1 (es) * 2006-11-01 2011-03-21 Ct Ingenieria Genetica Biotech Anticuerpos recombinantes contra el factor de crecimiento del endotelio vascular (vegf)
WO2008105248A1 (ja) 2007-02-27 2008-09-04 Nikon Corporation ズームレンズと、これを有する光学装置
US9209965B2 (en) 2014-01-14 2015-12-08 Microsemi Semiconductor Ulc Network interface with clock recovery module on line card

Also Published As

Publication number Publication date
JP6082698B2 (ja) 2017-02-15
KR20140019316A (ko) 2014-02-14
KR101896108B1 (ko) 2018-09-10
UY33844A (es) 2012-07-31
US20140086829A1 (en) 2014-03-27
MX2013007645A (es) 2013-12-02
ZA201305031B (en) 2014-03-26
US9505830B2 (en) 2016-11-29
JP2014504498A (ja) 2014-02-24
AU2011352474A1 (en) 2013-08-15
AU2011352474B2 (en) 2017-02-16
CN103370336A (zh) 2013-10-23
CA2823233C (en) 2020-06-09
TW201305203A (zh) 2013-02-01
RU2557309C2 (ru) 2015-07-20
WO2012089176A1 (es) 2012-07-05
EP2662388A1 (en) 2013-11-13
EP2662388B1 (en) 2018-08-22
AR084618A1 (es) 2013-05-29
TWI555757B (zh) 2016-11-01
CN103370336B (zh) 2015-11-25
CU20100264A7 (es) 2012-07-31
RU2013134983A (ru) 2015-02-10
CU23895B1 (es) 2013-05-31
MY166550A (en) 2018-07-16
CA2823233A1 (en) 2012-07-05
ES2687183T3 (es) 2018-10-24
BR112013016684A2 (pt) 2017-06-06

Similar Documents

Publication Publication Date Title
MX344915B (es) Anticuerpos recombinantes contra el factor de crecimiento del endotelio vascular (vegf) obtenidos mediante mutagenesis de regiones variables.
CY1124681T1 (el) Διειδικα αντισωματα anti-vegf/anti-ang-2 και η χρηση τους στην αγωγη οφθαλμικων αγγειακων νοσων
EP2579895A4 (en) ANTI-VEGF ANTIBODIES AND USES THEREOF
CY1124028T1 (el) Συνθεσεις και μεθοδοι για τα αντισωματα που στοχευουν την ερο
MX2017013471A (es) Metodo de secuenciamiento, determinacion, apareamiento y validacion de agentes terapeuticos y antigenos especificos de enfermedades.
NZ738979A (en) Pd-1 antibodies
PH12015501493B1 (en) Anti-pdgfr-beta antibodies and uses thereof
EA201391175A1 (ru) Гетеродимерные иммуноглобулины
CA2886433C (en) Human monoclonal anti-pd-l1 antibodies and methods of use
MX347515B (es) Agentes que se unen al receptor encrespado y usos de los mismos.
MX2016012830A (es) Anticuerpos contra el receptor 2 del factor de crecimiento epidermico humano (her2) biespecificos.
UA118029C2 (uk) Модифіковане антитіло, що зв'язується з людським fcrn, й способи його застосування
NZ706377A (en) Il-6 antagonists and uses thereof
MX353278B (es) Raton con cadena ligera comun.
CR20210097A (es) Anticuerpos y conjugados de anticuerpo y fármaco anti-egfr
MX2016008098A (es) Anticuerpos biespecificos del receptor 2 de factor de crecimiento ipidermico himano (her2) y metodo de uso.
MX369148B (es) Agentes de unión kir3dl2.
MX358728B (es) Composiciones de anticuerpos pan-receptor del factor de crecimiento epidermico humano (pan-her) humanizados.
EA201491569A1 (ru) МОДИФИЦИРОВАННЫЕ БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА IgG4 С СИММЕТРИЧНОЙ ПОСЛЕДОВАТЕЛЬНОСТЬЮ
EA201791393A3 (ru) Антитела к erbb3 и их применение
EA201591113A1 (ru) Антитела против антигена 2 дендритных клеток крови и их применение
EA201491107A1 (ru) Антитела к рецептору эпидермального фактора роста 3 (her3), направленные на домен ii her3
UA113879C2 (xx) ГУМАНІЗОВАНЕ АНТИТІЛО ПРОТИ ТrkА З АМІНОКИСЛОТНИМИ ЗАМІЩЕННЯМИ
PH12015500752A1 (en) Her3 antigen binding proteins binding to the beta-hairpin of her3
WO2014062659A3 (en) Methods of treating ocular diseases

Legal Events

Date Code Title Description
FG Grant or registration